Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2003
06/19/2003US20030114363 Water soluble paclitaxel derivatives
06/19/2003US20030113940 Antibodies specific for nanotubes and related methods and compositions
06/19/2003US20030113872 Vasopermeability-enhancing conjugates
06/19/2003US20030113845 Lyases; bactericides; gene knockout; animal husbandry
06/19/2003US20030113820 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
06/19/2003US20030113819 Carrier peptide and method for delivery of molecules into cells
06/19/2003US20030113818 Monoclonal anti-idiotypic antibody; antitumor agents; anticarcinogenic agents; antiproliferative agents; immunotherapy; hormone antagonist therapy
06/19/2003US20030113812 Evaluating modulators of neuron propagation; bone morphogenetic proteins; epidermal growth factors; erythropoietins; pleiotrophins; hepatocyte growth factors; somatomedins; nerve growth factors; interleukins
06/19/2003US20030113777 Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
06/19/2003US20030113714 Binding peptides to polycrystalline semiconductors; detection of bacteriophages; high density magnetic storage; medical imaging; forensics; antitumor agents; anticarcinogenic agents
06/19/2003US20030113445 Powder material for electrostatic application to a substrate and electrostatic application of the powder material to a substrate
06/19/2003US20030113384 Antimicrobial compositions for mastitis control
06/19/2003US20030113380 Microparticles comprising polymeric binder and injection vehicle, wherein microparticles are suspended in vehicle at concentration of greater than 30 mg/ml to form suspension having viscosity of 600 cp at 20 degrees C
06/19/2003US20030113377 Orally administered liquid compositions
06/19/2003US20030113376 Omeprazole formulation
06/19/2003US20030113375 Pharmaceutical formulation and process
06/19/2003US20030113372 Analgesic in admixture with injectable oil; nalbuphine free base or a pharmaceutically acceptable salt
06/19/2003US20030113368 Holding capability for hydrophilic and lipophilic drugs, water-soluble and hydrophobic substaces; controlling sustained release
06/19/2003US20030113367 Transmucosal delivery of an inclusion complex of alprazolam and a water soluble cyclodextrin(s); anxiolytic agents
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113365 Copolymer of alkyl (meth)acrylate and pyrrolidonoethyl (meth)acrylate; transdermal drug delivery device
06/19/2003US20030113361 Palatable arginine compounds and uses thereof for cardiovascular health
06/19/2003US20030113355 Nontoxic vernix compositions and method of producing
06/19/2003US20030113351 Lipid carrier
06/19/2003US20030113349 Reducing dermal and subdermal glandular secretions
06/19/2003US20030113339 Methods to improve immunogenicity of antigens and specificity of antibodies
06/19/2003US20030113337 High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
06/19/2003US20030113335 A conjugate molecule comprising an antitumor drug, a polyglutamate polymer and a targeting molecule; antitumor agents, treating autoimmune disorders such as rheumatoid arthritis, restenosis prevention
06/19/2003US20030113333 A kit containing a binding protein and a carrier molecule, binds with a hapten moiety and binds with a target antigen; monoclonal antibodies and engineered antibodies
06/19/2003US20030113316 Stable lyophilized pharmaceutical formulation of IgG antibodies
06/19/2003US20030113314 Heparin directly linked to antithrombin III by a covalent linkage comprises atleast one primary amino group, via a linkage between primary amino group of antithrombin III and terminal residue of heparin; anticoagulant; prosthetics
06/19/2003US20030113285 For silicone-free cosmetics, drugs
06/19/2003US20030113278 Treatment of excessive radiation (e.g. sunburn) exposure
06/19/2003US20030113276 Flexible polybutene strips for preventing gingivitis/whitening of teeth
06/19/2003US20030113273 Aerosolized dry powders for high speed absorption
06/19/2003US20030113269 Medical combinations comprising tiotropium and fluticasone proprionate
06/19/2003US20030113262 Gpib-lipid bond construct and use thereof
06/19/2003CA2469802A1 A structure for presenting desired peptide sequences
06/19/2003CA2469792A1 In vitro production of dendritic cells from cd14+ monocytes especially for the preparation of suspension, monolayer and three-dimensional cell and/or tissue models, and use of these models
06/19/2003CA2469613A1 Process for affecting neurologic progression
06/19/2003CA2469588A1 Highly concentrated stable meloxicam solutions for needleless injection
06/19/2003CA2469491A1 Composition for viral preservation
06/19/2003CA2469387A1 In situ bonds
06/19/2003CA2469336A1 Guanidinium transport reagents and conjugates
06/19/2003CA2469266A1 The method of treating cancer
06/19/2003CA2469204A1 Prospective identification and characterization of breast cancer stem cells
06/19/2003CA2467614A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003CA2467245A1 Prevention of flap necrosis in plastic surgery
06/18/2003EP1319410A1 Use of micro-organisms for a directed delivery of substances to specific parts of the gut
06/18/2003EP1319403A1 Remedies for cisplatin-tolerant cancer
06/18/2003EP1319399A1 Medicinal composition
06/18/2003EP1318973A2 Novel alkanoic acid derivatives
06/18/2003EP1318843A2 Acryl adhesive useful in transdermal drug delivery systems
06/18/2003EP1318838A1 Use of a nucleic acid/pei complex
06/18/2003EP1318827A1 Polymer-modified synthetic proteins
06/18/2003EP1318818A1 Diphosphonate solutions
06/18/2003EP1318817A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
06/18/2003EP1318813A1 Stable pergolide mesylate and process for making same
06/18/2003EP1318805A2 Pharmaceutical composition containing citalopram
06/18/2003EP1318801A2 Topical analgesic compositions containing aliphatic polyamines and methods of using same
06/18/2003EP1318796A2 Polynucleotide intercalator interceptors and inhibitors
06/18/2003EP1318788A1 Solid dose nanoparticulate compositions
06/18/2003EP1318787A2 Pharmaceutical suspension compositions lacking a polymeric suspending agent
06/18/2003EP1318785A2 Pulmonary delivery in treating disorders of the central nervous system
06/18/2003EP1318725A2 Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
06/18/2003EP1318721A1 Method of blocking free radical processes which result in mediated pathology without deleterious pro-oxidant side reactions
06/18/2003EP1275377B1 Granulates containing liposoluble substances and process of preparation thereof
06/18/2003EP1237585B1 Mineral-polymer hybrid composition
06/18/2003EP1225898B1 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
06/18/2003EP1212095B1 Process to make a sustained release formulation
06/18/2003EP1200317B1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids
06/18/2003EP0980376B1 Method for producing carbohydrate partial esters
06/18/2003EP0979032B1 Method of making controlled release devices
06/18/2003EP0954287B1 Controlled release composition
06/18/2003EP0936902B1 Spray-dried microparticles as therapeutic vehicles for use in gene therapy
06/18/2003EP0920623B1 Boron neutron capture therapy using pre-targeting methods
06/18/2003EP0904059B1 Improvement in the taste of active pharmaceutical ingredients
06/18/2003EP0800545B1 Targeted magnetically labeled molecular marker systems for the nmr imaging
06/18/2003CN1424926A Synergistic inhibition of viral replication long-chain hydrocarbons and nucleoside analogs
06/18/2003CN1424921A 有色眼科产品 Colored ophthalmic products
06/18/2003CN1424915A Oral, nasal and pulmonary dosage formulations of copolymer1
06/18/2003CN1424914A Carbon dioxide enhancement of inhalation therapy
06/18/2003CN1424909A Formulations for use in inhaler devices
06/18/2003CN1424908A Patch containing anti-inflammatory agent
06/18/2003CN1424907A Improved pharmaceutical formulations
06/18/2003CN1424903A Personal care articles comprising cationic polymer coacervate compositions
06/18/2003CN1424112A Water soluble dressing for insoluble medicines and preparation thereof
06/18/2003CN1424111A Hyacinth bletilla micro-balls for liver and kidney arterial embolism
06/18/2003CN1424046A Use of Chinese angelica polysaccharide in oral colon orientation releasing pro-drug
06/18/2003CN1424037A Water soluble dressing materials of ziracitone and its salts and their preparation
06/18/2003CN1111430C Globular cellulose DNA immunoadsorbent
06/18/2003CN1111413C Anion exchange resin-containing tablets
06/18/2003CN1111404C Controlled release oxybutynin formulation
06/18/2003CN1111357C Food products having enhanced cocoa polyphenol content and processes for producing same
06/17/2003US6579953 Graft polymers; improved flowability, greater hardness and less friability
06/17/2003US6579907 Foaming oil-in-water emulsion based on nonionic surfactants, a fatty phase and a crosslinked cationic or anionic polymer, and its use in topical applications
06/17/2003US6579906 Stability, nontoxic; anthrax
06/17/2003US6579901 Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye
06/17/2003US6579895 Orally administration to provide a blood plasma concentration profile of celecoxib of at least about 250 mg/ml in not more than about 30 minutes
06/17/2003US6579865 For use in transdermally and topically applied drug delivery
1 ... 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 ... 1712